Journal
JOURNAL OF LAW MEDICINE & ETHICS
Volume 47, Issue 3, Pages 393-395Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1073110519876170
Keywords
-
Categories
Funding
- Yale University from Johnson and Johnson
- Medtronic, Inc.
- Food and Drug Administration (FDA) [U01FD004585]
- Food and Drug Administration [U01FD005938]
- Blue Cross Blue Shield Association
- Centers of Medicare and Medicaid Services (CMS) [HHSM-500-2013-13018I]
- Agency for Healthcare Research and Quality [R01HS022882]
- National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) [R01HS025164]
- Laura and John Arnold Foundation
- FDA Yale-Mayo Clinic CERSI [U01FD005938]
Ask authors/readers for more resources
Surrogate endpoints are a common application of biomarkers to estimate clinical benefit in clinical trials, despite questions about reliability. This article discusses ongoing opportunities for their validation, in the context of a regulatory environment in which they are increasingly championed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
